Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
8389.75 | 1,20,632 Cr | 62.13 | 12.74 | 0.24 | 20.48 | 17.27 | 9.02 | ||
1025.00 | 99,631 Cr | 69.07 | 9.27 | 0.20 | 13.42 | 12.97 | 8.37 | ||
968.10 | 73,148 Cr | 70.21 | 7.39 | 0.10 | 10.53 | 12.56 | 6.67 | ||
777.00 | 40,395 Cr | 104.07 | 9.56 | 0.38 | 8.48 | 10.10 | 5.27 | ||
1863.50 | 38,070 Cr | 47.26 | 8.39 | 0.24 | 17.76 | 11.42 | 6.46 | ||
1245.00 | 33,219 Cr | 59.70 | 8.39 | 0.00 | 14.05 | 15.26 | 9.38 | ||
778.15 | 31,137 Cr | 128.98 | 13.85 | 0.00 | 10.74 | 7.99 | 3.12 | ||
| Median: 7 Co. | — | 1025.00 | 40,395 Cr | 69.07 | 9.27 | 0.20 | 13.42 | 12.56 | 6.67 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Fortis Healthcare Ltd (FORTIS) is currently trading at 949.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Fortis Healthcare is a leading integrated healthcare delivery provider in India operating 36 facilities across 12 states with over 6,000 operational beds (including O&M) and a large diagnostics franchise, offering multi‑specialty and quaternary services across Cardiac, Oncology, Neuro, Renal and other specialties under an integrated hospital and diagnostics model. Q3 FY26 results show healthy top‑line and margin expansion: consolidated revenue grew 17.5% YoY to INR 2,265 Cr while operating EBITDA rose 34.8% to INR 505 Cr with a 22.3% margin; hospital revenues grew 19.4% and hospital EBITDA margin expanded to 21.7%, signaling improving operating leverage at Fortis Healthcare. Diagnostics under Agilus is improving materially with gross revenues of INR 371 Cr, 9.9 million tests in the quarter, network expansion to 4,370 customer touchpoints and a meaningful margin step‑up driven by automation, specialized tests and higher preventive portfolio contribution; Fortis Healthcare has also scaled NGS capability via Illumina NovaSeq X to bolster high‑throughput genomics. Fortis Healthcare is executing a cluster‑based inorganic strategy: the Jan’26 People Tree Bengaluru acquisition (125 beds, expandable to 300) and other acquisitions plus brownfield projects (FMRI tower, Manesar, Noida expansions) added ~750 beds YTD and pushed net debt to INR 2,547 Cr, reflecting deliberate balance‑sheet deployment to accelerate scale across existing clusters. Margin concentration is notable: 13 facilities delivered >20% EBITDA and accounted for ~77% of hospital revenues in 9MFY26, while digital channels contribute ~30% of hospital revenue; Fortis Healthcare is leveraging specialty clustering, digital channels, and high‑value case mix (robotic and complex surgeries) to drive ARPOB and margins.
Over the past 52 weeks, Fortis Healthcare Ltd has traded between a low of ₹741.45 and a high of ₹1,105.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Fortis Healthcare Ltd has a market capitalization of approximately 73,147.89. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Fortis Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 70.21 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 73,147.89 Cr, Fortis Healthcare Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Fortis Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Fortis Healthcare Ltd is 70.21. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Fortis reported Q4 FY26 revenue from operations of ₹2,365 crore and PAT of ₹271 crore, compared with ₹2,007 crore revenue and ₹188 crore PAT in Q4 FY25.
Fortis reported Q4 FY25 revenue from operations of INR 2,007 crore, up 12.4% year-on-year, while consolidated net profit fell 7.4% to INR 188.02 crore.
IHH Healthcare holds a 31.17% stake in Fortis Healthcare and a 62.73% stake in its subsidiary, Fortis Malar Hospitals, making it the largest shareholder.
The key announcement was the proposal to establish five regional medical value tourism hubs in India through a public-private partnership model, which is expected to directly benefit hospital chains like Fortis.
Fortis Healthcare is a leading integrated healthcare delivery provider in India operating 36 facilities across 12 states with over 6,000 operational beds (including O&M) and a large diagnostics franchise, offering multi‑specialty and quaternary services across Cardiac, Oncology, Neuro, Renal and other specialties under an integrated hospital and diagnostics model.
Q3 FY26 results show healthy top‑line and margin expansion: consolidated revenue grew 17.5% YoY to INR 2,265 Cr while operating EBITDA rose 34.8% to INR 505 Cr with a 22.3% margin; hospital revenues grew 19.4% and hospital EBITDA margin expanded to 21.7%, signaling improving operating leverage at Fortis Healthcare.
Diagnostics under Agilus is improving materially with gross revenues of INR 371 Cr, 9.9 million tests in the quarter, network expansion to 4,370 customer touchpoints and a meaningful margin step‑up driven by automation, specialized tests and higher preventive portfolio contribution; Fortis Healthcare has also scaled NGS capability via Illumina NovaSeq X to bolster high‑throughput genomics.
Fortis Healthcare is executing a cluster‑based inorganic strategy: the Jan’26 People Tree Bengaluru acquisition (125 beds, expandable to 300) and other acquisitions plus brownfield projects (FMRI tower, Manesar, Noida expansions) added ~750 beds YTD and pushed net debt to INR 2,547 Cr, reflecting deliberate balance‑sheet deployment to accelerate scale across existing clusters.
Margin concentration is notable: 13 facilities delivered >20% EBITDA and accounted for ~77% of hospital revenues in 9MFY26, while digital channels contribute ~30% of hospital revenue; Fortis Healthcare is leveraging specialty clustering, digital channels, and high‑value case mix (robotic and complex surgeries) to drive ARPOB and margins.
Healthcare Services
Hospital
73,148 Cr
Low Risk
70.2
58.7
2.5
7.4
1,105.00
741.45
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
4
Neutral
8
Bullish
2
Bearish
23
Neutral
8
Bullish
15
Bearish
19
Neutral
0
Bullish
13
